A follow-up study on the long-term effects of a single dose of psilocybin on depression, indicating sustained relief for up to five years.

Study examining psilocybin-assisted therapy for addressing burnout and mental health challenges in healthcare workers

Comprehensive survey study examining DMT's impact on depression, anxiety, and overall mental health in adult users

Groundbreaking study measuring endogenous DMT concentrations in human brain tissue, finding levels nearly double that of dopamine

Clinical trial investigating IV DMT administration for treatment-resistant depression

Controlled study examining the effects of psilocybin microdosing on anxiety symptoms and daily functioning

Observational study of a single ibogaine treatment in 30 special operations veterans with PTSD and traumatic brain injury. Produced dramatic reductions in PTSD severity, depression, and anxiety while improving cognitive function. Effect sizes were substantially larger than any conventional PTSD treatment.

Landmark study examining ibogaine's efficacy in treating PTSD and traumatic brain injury in military veterans

Clinical study showing 5-MeO-DMT's potential for providing extended relief in treatment-resistant depression cases

Clinical investigation of psilocybin's efficacy in treating chronic neuropathic pain conditions

Long-term follow-up study showing sustained antidepressant effects of single psilocybin dose in cancer patients with depression

A case study examining the potential of 5-MeO-DMT as a therapeutic intervention for individuals with treatment-resistant Post-Traumatic Stress Disorder (PTSD).

A clinical trial to evaluate the safety, tolerability, and efficacy of 5-MeO-DMT in patients with probable Alzheimer's Disease.

A study investigating the neural dynamics of the DMT-induced state of consciousness using high-density EEG.

Comprehensive safety assessment of 5-MeO-DMT in therapeutic contexts

Phase 3 randomised controlled trial of MDMA-assisted therapy (MDMA-AT) for severe PTSD. 104 participants with severe or extreme PTSD randomised to MDMA-AT or placebo-assisted therapy across multiple sites.

Systematic review of published research on 5-MeO-DMT covering effects, pharmacology, subjective experience, and safety profile. Found generally favorable safety profile in supervised settings and promising therapeutic potential, particularly for existential distress and depression.

Review examining the molecular and cellular mechanisms by which psychedelics produce rapid and sustained changes in neural plasticity. Covers BDNF upregulation, TrkB receptor signaling, synaptogenesis, and the 'critical period reopening' hypothesis that may explain why early life experiences can be revisited and reprocessed.

Phase 2b randomized dose-finding trial of COMP360 (synthetic psilocybin) for treatment-resistant depression. The 25mg dose produced significantly greater antidepressant response than 1mg (active control) at 3 weeks, with a meaningful response rate maintained at 12 weeks.

Phase 2 trial showing significant antidepressant effects of psilocybin in treatment-resistant depression

A single dose modulated amygdala-prefrontal circuitry, correlating with antidepressant effects. (Daws et al., 2022)

A phase 2 randomized controlled trial investigating psilocybin therapy for treatment-resistant depression, showing significant and sustained reduction in depressive symptoms.

Microdoses produced mild subjective enhancements in mood and cognition without impairing performance. (Hutten et al., 2021)

Randomized trial reported 71% response rate with psilocybin in major depressive disorder patients. (Davis et al., 2021)

Preclinical and clinical studies support ayahuasca's efficacy in reducing substance use behaviors. (Perkins et al., 2021)

Landmark randomized controlled trial comparing two doses of psilocybin versus six weeks of escitalopram (Lexapro) in 59 patients with major depressive disorder. Psilocybin produced equivalent antidepressant effects with a notably more favorable emotional side effect profile — patients reported more emotional depth and well-being.

Phase 3 trial demonstrating the efficacy and safety of MDMA-assisted therapy for participants with severe PTSD.

Innovative citizen science study where participants prepared their own microdose and placebo capsules in a self-blinding protocol. Found that while open-label microdosing produced improvements, blinded conditions showed no significant difference from placebo — suggesting expectancy effects account for much of the reported benefit.

Self-blinded citizen science study of LSD microdosing using a novel within-subject placebo-controlled design. 191 participants completed the study over 6 weeks using a novel app-based protocol.

Systematic review of psychedelic therapy research for cancer-related psychological distress.

Clinical trials show psilocybin is generally safe with mild-to-moderate transient adverse effects. (Dos Santos & Hallak, 2020)

Abstract not available.

Randomized, double-blind, placebo-controlled trial of ayahuasca for treatment-resistant major depressive disorder. Significant antidepressant effects at 1 day and 7 days post-treatment compared to placebo. First RCT of ayahuasca for depression.

DMT imaging revealed increased global functional connectivity during acute administration. (Timmermann et al., 2019)

Phase 2 multi-site randomised controlled trial of MDMA-assisted psychotherapy for PTSD across 6 sites in US, Canada and Israel. 131 participants with chronic PTSD.

Survey indicates 70% of microdosers report improved mood, focus, and creativity with minimal adverse events. (Polito & Stevenson, 2019)

MDMA-assisted therapy reduced social anxiety symptoms in autistic adults by 60% compared to placebo. (Danforth et al., 2018)

Survey study of 5-MeO-DMT users examining psychological outcomes and experiences

Mystical-type experiences combined with spiritual practices led to lasting positive personality changes. (Griffiths et al., 2018)

Observational study of ibogaine treatment for opioid addiction showing promising outcomes

Evidence indicates low abuse liability with controlled administration and medical oversight. (Johnson & Griffiths, 2017)

80% of participants remained abstinent at 12-month follow-up after psilocybin-facilitated smoking cessation. (Johnson et al., 2017)

Systematic review and meta-analysis of randomised controlled trials examining cannabis-based medicines for chronic non-cancer pain.

Comprehensive review of ketamine's antidepressant mechanism and clinical evidence. Covers NMDA receptor antagonism, downstream synaptic plasticity mechanisms, and the clinical data supporting its use in treatment-resistant depression. Foundation for FDA esketamine approval.

Review highlights mechanisms by which ayahuasca compounds modulate neuroplasticity and mood. (dos Santos et al., 2016)

Double-blind trial at Johns Hopkins showing a single high-dose psilocybin session produced large, significant, and sustained decreases in depressed mood and anxiety in cancer patients, along with increases in quality of life, life meaning, and optimism.

Open-label study demonstrated feasibility and safety of psilocybin in treatment-resistant depression, showing significant mood improvements. (Carhart-Harris et al., 2016)

Single psilocybin dose produced rapid and sustained reduction in depression and anxiety in cancer patients for up to 6 months. (Griffiths et al., 2016)

This review summarizes human studies showing ayahuasca's antidepressant, anxiolytic, and anti-addictive properties. (Frecska et al., 2016)

Double-blind, randomised, placebo-controlled study in 40 healthy subjects examining LSD's effects on emotional processing including fear recognition, empathy, and social behaviour.

In vitro study demonstrating neuroprotective effects of DMT on human cortical neurons

Neuroimaging study exploring the neural correlates of ego dissolution during LSD administration.

Landmark neuroimaging study of LSD effects using fMRI, MEG and ASL in 20 healthy volunteers receiving 75μg intravenous LSD or placebo in a double-blind crossover design.

Online survey of 1993 individuals who reported difficult psilocybin experiences. Found that while challenging experiences are common and can be severe, the majority of respondents attributed lasting positive meaning to them. Provides important data on the prevalence and nature of challenging psychedelic experiences.

Patients reported increased anxiety reduction and subjective well-being lasting up to 3 months post-treatment. (Gasser et al., 2015)

Preclinical and clinical evidence review for CBD as a treatment for multiple anxiety disorders including PTSD, GAD, social anxiety, panic disorder, and OCD.

Psilocybin-assisted therapy showed reduced alcohol cravings and improved drinking behaviors in a small cohort. (Bogenschutz et al., 2015)

SPECT imaging showed acute increases in cerebral blood flow correlating with antidepressant response. (Osório et al., 2015)

Study examining whether LSD increases suggestibility, a property potentially relevant to its psychotherapeutic mechanism. 10 healthy volunteers received 75μg LSD and completed standardised suggestibility measures.

5-HT2A antagonists reduced visual hallucination severity without worsening motor symptoms. (Meltzer & Toth, 2014)

A double-blind, randomised, active placebo-controlled pilot study investigating LSD-assisted psychotherapy in 12 patients with anxiety associated with life-threatening illnesses. Patients received two LSD-assisted psychotherapy sessions (200μg active vs 20μg placebo).

Double-blind, randomised, placebo-controlled study examining MDMA's acute effects on social cognition, trust behaviour and empathy in 32 healthy male volunteers.

Ibogaine reduced withdrawal symptoms in opioid-dependent subjects with sustained abstinence at 12-month follow-up. (Brown, 2013)

fMRI studies revealed decreased Default Mode Network connectivity correlating with subjective psychedelic experiences. (Carhart-Harris et al., 2012)

Pilot study examining MDMA-assisted psychotherapy for treatment-resistant PTSD patients.

Comprehensive review of salvinorin A pharmacology and potential therapeutic applications

Ketamine dose produced significant mood elevation within 40 minutes in bipolar II patients. (Zarate et al., 2006)

Study examining psychological outcomes in Native American Church members who use peyote

Ketamine demonstrated rapid antidepressant effects lasting up to 1 week post-administration. (Berman et al., 2000)

Ibogaine exhibited long-lasting reductions in drug-seeking behaviors in animal models and case reports. (Glick et al., 1994)